Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
AstraZeneca
Medtronic
Harvard Business School
McKesson

Last Updated: May 26, 2022

CYSVIEW KIT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Cysview Kit, and when can generic versions of Cysview Kit launch?

Cysview Kit is a drug marketed by Photocure Asa and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-seven patent family members in fifteen countries.

The generic ingredient in CYSVIEW KIT is hexaminolevulinate hydrochloride. One supplier is listed for this compound. Additional details are available on the hexaminolevulinate hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Cysview Kit

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 19, 2036. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Drug patent expirations by year for CYSVIEW KIT
DrugPatentWatch® Estimated Generic Entry Opportunity Date for CYSVIEW KIT
Generic Entry Date for CYSVIEW KIT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
FOR SOLUTION;INTRAVESICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for CYSVIEW KIT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
KARL STORZ Endoscopy-America, Inc.Phase 2
Dr. Te VuongPhase 2
PhotocurePhase 3

See all CYSVIEW KIT clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for CYSVIEW KIT

US Patents and Regulatory Information for CYSVIEW KIT

CYSVIEW KIT is protected by two US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of CYSVIEW KIT is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting CYSVIEW KIT

Neoadjuvant therapy for bladder cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY

Method of photodynamic therapy (PDT) for bladder cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CYSVIEW KIT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 See Plans and Pricing See Plans and Pricing
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 See Plans and Pricing See Plans and Pricing
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 See Plans and Pricing See Plans and Pricing
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for CYSVIEW KIT

When does loss-of-exclusivity occur for CYSVIEW KIT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 16372573
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2018012009
Estimated Expiration: See Plans and Pricing

Canada

Patent: 08551
Estimated Expiration: See Plans and Pricing

China

Patent: 8601836
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 89717
Estimated Expiration: See Plans and Pricing

Japan

Patent: 26086
Estimated Expiration: See Plans and Pricing

Patent: 18537514
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 18124868
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 180094987
Estimated Expiration: See Plans and Pricing

United Kingdom

Patent: 1522309
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering CYSVIEW KIT around the world.

Country Patent Number Title Estimated Expiration
Denmark 3389716 See Plans and Pricing
Russian Federation 2018123834 СПОСОБ ФОТОДИНАМИЧЕСКОЙ ТЕРАПИИ (ФДТ) ДЛЯ РАКА МОЧЕВОГО ПУЗЫРЯ See Plans and Pricing
China 108601836 用于膀胱癌的新辅助疗法 (Neoadjuvant therapy for bladder cancer) See Plans and Pricing
Israel 259925 שיטת טיפול פוטודינמי עבור סרטן שלפוחית השתן (Method of photodynamic therapy (pdt) for bladder cancer) See Plans and Pricing
Russian Federation 2191010 5-AMINOLEVULINIC ACID ESTERS AS PHOTOSENSIBILIZING AGENTS IN PHOTOCHEMOTHERAPY See Plans and Pricing
Hungary 9800460 See Plans and Pricing
China 108697800 用于膀胱癌的光动力疗法(PDT)的方法 (METHOD OF PHOTODYNAMIC THERAPY (PDT) FOR BLADDER CANCER) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for CYSVIEW KIT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0820432 300207 Netherlands See Plans and Pricing 300207, 20160308, EXPIRES: 20190916
0820432 SPC/GB05/044 United Kingdom See Plans and Pricing PRODUCT NAME: HEXYL AMINOLEVULINATE, OPTIONALLY IN THE FORM OF A SALT, PREFERABLY HEXYL AMINOLEVULINATE HYDROCHLORIDE; REGISTERED: SE 19227 20040917; UK PL 18952/0003 20050714
0820432 SPC024/2002 Ireland See Plans and Pricing SPC024/2002: 20041230, EXPIRES: 20160614
0820432 05C0042 France See Plans and Pricing PRODUCT NAME: HEXYL AMINOLEVULINATE; NAT. REGISTRATION NO/DATE: NL 30979 20050812; FIRST REGISTRATION: SE - 19 227 20040917
0820432 300176 Netherlands See Plans and Pricing 300176, 20160308, EXPIRES: 20160614
0820432 SPC019/2008 Ireland See Plans and Pricing SPC019/2008: 20090219, EXPIRES: 20190916
0820432 07C0010 France See Plans and Pricing PRODUCT NAME: AMINOLEVULINATE DE METHYLE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 30885 20060919; FIRST REGISTRATION: SE - 16338 20010615
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Baxter
Johnson and Johnson
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.